CN112153984A - 化合物及其用途 - Google Patents

化合物及其用途 Download PDF

Info

Publication number
CN112153984A
CN112153984A CN201980023925.9A CN201980023925A CN112153984A CN 112153984 A CN112153984 A CN 112153984A CN 201980023925 A CN201980023925 A CN 201980023925A CN 112153984 A CN112153984 A CN 112153984A
Authority
CN
China
Prior art keywords
optionally substituted
compound
cancer
μmol
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980023925.9A
Other languages
English (en)
Chinese (zh)
Inventor
N·J·安东尼
D·S·米兰
R·G·瓦斯瓦尼
S·E·R·席勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuhong Treatment Co
Original Assignee
Fuhong Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuhong Treatment Co filed Critical Fuhong Treatment Co
Publication of CN112153984A publication Critical patent/CN112153984A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
    • A61B2018/00589—Coagulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
CN201980023925.9A 2018-01-30 2019-01-29 化合物及其用途 Pending CN112153984A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862623907P 2018-01-30 2018-01-30
US62/623907 2018-01-30
US201862653229P 2018-04-05 2018-04-05
US62/653229 2018-04-05
US201862770431P 2018-11-21 2018-11-21
US62/770431 2018-11-21
US201962789260P 2019-01-07 2019-01-07
US62/789260 2019-01-07
PCT/US2019/015722 WO2019152437A1 (en) 2018-01-30 2019-01-29 Compounds and uses thereof

Publications (1)

Publication Number Publication Date
CN112153984A true CN112153984A (zh) 2020-12-29

Family

ID=67478426

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980023925.9A Pending CN112153984A (zh) 2018-01-30 2019-01-29 化合物及其用途

Country Status (5)

Country Link
US (2) US11497752B2 (https=)
EP (1) EP3746124A4 (https=)
JP (1) JP2021512166A (https=)
CN (1) CN112153984A (https=)
WO (1) WO2019152437A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087885A1 (en) 2015-11-19 2017-05-26 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019152437A1 (en) 2018-01-30 2019-08-08 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020081588A1 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
BR112021010453A2 (pt) 2018-12-19 2021-08-24 Leo Pharma A/S Composto, e, composição farmacêutica
EP3917517A4 (en) 2019-01-29 2023-01-25 Foghorn Therapeutics Inc. CONNECTIONS AND USES THEREOF
CN113874016A (zh) 2019-01-29 2021-12-31 福宏治疗公司 化合物及其用途
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
ES3032327T3 (en) 2019-01-29 2025-07-17 Foghorn Therapeutics Inc Compounds and uses thereof
WO2020160100A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021022163A2 (en) 2019-07-31 2021-02-04 Foghorn Therapeutics Inc. Compounds and uses thereof
JP7842684B2 (ja) * 2019-09-11 2026-04-08 ビンシア・バイオサイエンシーズ・インコーポレイテッド Ｕｓｐ３０阻害剤及びその使用
BR112022012410A2 (pt) 2019-12-23 2022-08-30 Kymera Therapeutics Inc Degradadores smarca e usos dos mesmos
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
CN115297861B (zh) 2020-01-29 2024-07-12 福宏治疗公司 化合物及其用途
US12528825B2 (en) 2020-01-29 2026-01-20 Foghorn Therapeutics Inc. Compounds and uses thereof
US20230121497A1 (en) 2020-01-29 2023-04-20 Foghorn Therapeutics Inc. Compounds and uses thereof
CA3167275A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
EP4097096A4 (en) * 2020-01-29 2024-02-28 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
AU2021214767A1 (en) 2020-01-29 2022-07-28 Foghorn Therapeutics Inc. Compounds and uses thereof
US20230149414A1 (en) 2020-01-29 2023-05-18 Foghorn Therapeutics Inc. Compounds and uses thereof
CN115867314A (zh) * 2020-05-20 2023-03-28 福宏治疗公司 治疗癌症的方法
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
WO2022079290A2 (en) * 2020-10-16 2022-04-21 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Cullin ring ubiquitin ligase compounds and uses thereof
JP7675182B2 (ja) * 2020-11-10 2025-05-12 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
EP4259144A4 (en) 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DEGRADING AGENTS AND THEIR USES
US20240383868A1 (en) * 2021-02-19 2024-11-21 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
JP2024509268A (ja) 2021-03-09 2024-02-29 フォグホーン セラピューティクス インコーポレイテッド 結晶形、それらを含有する組成物、及びそれらの使用方法
WO2023283263A1 (en) 2021-07-06 2023-01-12 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
WO2023009834A2 (en) * 2021-07-29 2023-02-02 Foghorn Therapeutics Inc. Methods of treating cancer
WO2024086577A1 (en) * 2022-10-17 2024-04-25 Foghorn Therapeutics Inc. Methods of reducing or preventing metastases
CN119768400A (zh) * 2022-11-11 2025-04-04 苏州信诺维医药科技股份有限公司 一种稠环化合物、其用途及含其的药物组合物
WO2025017207A1 (en) * 2023-07-20 2025-01-23 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Inhibitors of smndc1 and their therapeutic use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717642A (en) * 1969-07-22 1973-02-20 Warner Lambert Co N quinoline 5 aminooxazoles
CN103038231A (zh) * 2010-03-17 2013-04-10 台维克斯医疗公司 Hec1活性调节剂及其方法
WO2015120320A1 (en) * 2014-02-06 2015-08-13 Rutgers, The State University Of New Jersey Antibacterial agents: n(alpha)-aroyl-n-aryl-phenylalaninamides
CN105473141A (zh) * 2013-03-15 2016-04-06 实发生物医学公司 治疗和/或预防心血管疾病的抗pcsk9化合物和方法
CN107531668A (zh) * 2015-02-25 2018-01-02 基因泰克公司 治疗性哒嗪化合物及其用途

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2788341A (en) * 1953-03-06 1957-04-09 Ciba Pharm Prod Inc Process for the manufacture of aminoacyl compounds
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4147343A (en) 1978-02-25 1979-04-03 Hyde Phillip R Acrobatic amusement device
FR2568880B1 (fr) 1984-08-07 1986-12-12 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
DE68905707T2 (de) 1988-08-10 1993-08-19 Tokyo Sintered Metals Corp Fahrradaehnliches trainingsgeraet.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5016870A (en) 1990-02-09 1991-05-21 Bulloch Russell G Exercise device
DE69210091T2 (de) * 1991-05-31 1996-10-02 Sumitomo Pharma Leukotrien-B4-Antagonisten
DE69326967T2 (de) 1992-01-17 2000-06-15 Lakowicz, Joseph R. Phasenmodulationsenergieübertragungsfluoroimmunassay
EP1362913B1 (en) 1992-10-30 2006-01-25 The General Hospital Corporation Interaction trap system for isolating proteins
US5569128A (en) 1994-02-03 1996-10-29 Icon Health & Fitness, Inc. Leg and upper body exerciser
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US5677158A (en) 1995-06-07 1997-10-14 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US6180612B1 (en) 1997-10-31 2001-01-30 The University Of Virginia Patent Foundation Methods and compositions for targeting DNA metabolic processes using aminoglycoside derivatives
US6683058B1 (en) 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
DE69929600T2 (de) 1998-05-27 2006-09-07 Avigen Inc., Alameda Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren
JP2000095767A (ja) 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
WO2000024392A1 (en) * 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited β-AMYLOID FORMATION INHIBITORS
AU4058000A (en) 1999-04-02 2000-10-23 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives: selective modulatorsof gabaa receptors
WO2000059888A1 (en) 1999-04-02 2000-10-12 Neurogen Corporation N-benzimidazolylmethyl- and n-indolylmethyl-benzamides and their use as crf modulators
WO2001059094A2 (en) 2000-02-11 2001-08-16 The Salk Institute For Biological Studies Method of regulating transcription in a cell by altering remodeling of cromatin
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6547702B1 (en) 2000-03-29 2003-04-15 Innovative Applications, Inc. Exercise device
US20020037281A1 (en) 2000-05-26 2002-03-28 Davidson Beverly L. Methods of transducing neural cells using lentivirus vectors
US20030027335A1 (en) 2000-09-07 2003-02-06 Ruley H. Earl Genome engineering by cell-permeable DNA site-specific recombinases
WO2002064834A1 (en) 2001-01-04 2002-08-22 Myriad Genetics, Inc. Novel two-hybrid system and use thereof
JP2003033179A (ja) 2001-07-05 2003-02-04 Asahi Kasei Corp 可逆的遺伝子導入ベクター
JP2003077651A (ja) 2001-08-30 2003-03-14 Sharp Corp 有機エレクトロルミネッセンス素子の製造方法
ES2367422T3 (es) 2001-10-09 2011-11-03 Amgen Inc. Derivados de imidazol como agentes antiinflamatorios.
US20050079512A1 (en) 2003-02-26 2005-04-14 Emerson Beverly M. Methods of modulating gene expression
WO2004078939A2 (en) 2003-03-03 2004-09-16 University Of Massachusetts REGULATION OF Mdm2 FUNCTION
US20050130919A1 (en) 2003-07-18 2005-06-16 University Of Massachusetts Regulatable promoters for synthesis of small hairpin RNA
WO2005039643A2 (en) 2003-10-20 2005-05-06 Nsgene A/S In vivo gene therapy of parkinson's disease
US20060058255A1 (en) 2004-03-01 2006-03-16 Jianzhu Chen RNAi-based therapeutics for allergic rhinitis and asthma
US20050289659A1 (en) 2004-05-18 2005-12-29 Jacks E T Cre-lox based method for conditional RNA interference
WO2006005941A1 (en) 2004-07-12 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. Amide derivatives as inhibitors of histone deacetylase
DK1814880T3 (da) 2004-11-11 2009-05-18 Ferrer Int Imidazo[1,2-a]pyridinforbindelser, og sammensætninger, anvendelser og fremgangsmåder, der er forbundet dermed
WO2006070806A1 (ja) 2004-12-28 2006-07-06 Taiho Pharmaceutical Co., Ltd. 新規ベンゾイミダゾール化合物及び該化合物を含有する医薬組成物
WO2006119435A2 (en) 2005-05-04 2006-11-09 Invitrogen Corporation Identification of cancer biomarkers and phosphorylated proteins
CN101528226B (zh) 2006-08-24 2012-01-11 澳大利亚核科学技术组织 靶向外周苯二氮卓受体的氟化配体
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
JP2010528051A (ja) 2007-05-23 2010-08-19 シガ・テクノロジーズ・インコーポレーテッド デング感染症の治療または予防のための抗ウイルス薬
US20090209536A1 (en) 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
US7927258B2 (en) 2007-08-17 2011-04-19 Real Ryder, LLC Bicycling exercise apparatus
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA2618163A1 (en) 2008-02-07 2009-08-07 K. W. Michael Siu Head and neck cancer biomarkers
ES2392482T3 (es) 2008-02-29 2012-12-11 Array Biopharma, Inc. Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF
EP2559455A1 (en) * 2008-07-15 2013-02-20 Novartis AG Heteroaryl derivatives as DGAT1 inhibitors
MX2011008204A (es) 2009-02-05 2011-12-06 Targeted Delivery Technologies Ltd Metodos para reducir la proliferacion y viabilidad de los agentes microbianos.
US20130197056A1 (en) 2010-04-22 2013-08-01 British Columbia Cancer Agency Branch Novel biomarkers and targets for ovarian carcinoma
WO2012015937A2 (en) 2010-07-29 2012-02-02 The Regents Of The University Of Michigan Parp1 targeted therapy
US9072052B2 (en) 2010-08-09 2015-06-30 Blackberry Limited Communication system providing context-based mobile wireless communications device power consumption management and related methods
US8647240B2 (en) 2010-10-08 2014-02-11 Innovative Applications, Inc. Exercise device
CN103429571A (zh) 2010-12-22 2013-12-04 普渡制药公司 作为钠通道阻断剂的取代吡啶
EP2694678A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
CN114262690A (zh) 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
US9403843B2 (en) 2012-02-01 2016-08-02 The Trustees Of Columbia University In The City Of New York Cysteine protease inhibitors and uses thereof
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
US9227106B2 (en) 2012-05-21 2016-01-05 Todd Richards Weight lifting machine
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
CA2894684A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
AU2013359262C1 (en) 2012-12-12 2021-05-13 Massachusetts Institute Of Technology CRISPR-Cas component systems, methods and compositions for sequence manipulation
US9410943B2 (en) 2013-03-14 2016-08-09 The Board Of Trustees Of The Leland Stanford Junior University Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma
EP2971094B1 (en) 2013-03-15 2021-09-15 Novartis AG Biomarkers associated with brm inhibition
US10976320B2 (en) 2013-05-21 2021-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods for identifying and treating cancer patients
ES2950424T3 (es) 2013-07-03 2023-10-09 Takeda Pharmaceuticals Co Compuesto de amida
US20160130663A1 (en) 2013-07-12 2016-05-12 National Cancer Center Method for predicting response to cancer treatment
EP3022197B1 (en) 2013-07-15 2017-09-06 Boehringer Ingelheim International GmbH Novel tetra- and pentasubstituted benzimidazolium compounds
WO2015046193A1 (ja) 2013-09-25 2015-04-02 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
BR112016015449A8 (pt) 2013-12-30 2020-06-09 Lifesci Pharmaceuticals Inc compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
GB201402771D0 (en) 2014-02-17 2014-04-02 Isis Innovation Biomarker & therapeutic target for sarcoma
US9546206B2 (en) 2014-08-08 2017-01-17 The Board Of Trustees Of The Leland Stanford Junior University High affinity PD-1 agents and methods of use
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9636323B2 (en) 2014-10-27 2017-05-02 Baylor College Of Medicine Method of treating cancer that overexpresses TopBP1
CN104530013B (zh) 2014-12-04 2016-06-29 中国农业大学 基于吲哚环的吡唑酰胺类化合物作为农用杀菌剂的用途
US9546296B2 (en) 2014-12-15 2017-01-17 Ppg Industries Ohio, Inc. Coating compositions, coatings and methods for sound and vibration damping and water resistance
US9932340B2 (en) 2014-12-18 2018-04-03 Abbvie Inc. Substituted indoles
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
US10363256B2 (en) * 2015-03-27 2019-07-30 University Of Washington Methods for treatment of retinal disease by photoreceptor gene expression modulation
WO2016164482A1 (en) 2015-04-06 2016-10-13 The University Of North Carolina At Chapel Hill Methods and compositions for treatment of heart failure
EP3108883A1 (en) * 2015-06-22 2016-12-28 Fundació Institut de Recerca Biomèdica de Bellvitge Therapeutic uses of non-peptide inhibitors of the calcineurin - nfat signalling pathway
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017024318A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
US9630049B2 (en) 2015-09-21 2017-04-25 Joseph D Hartman Reciprocating rehabilitation device
US20170100396A1 (en) 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza
SG11201803088PA (en) 2015-10-15 2018-05-30 Agios Pharmaceuticals Inc Combination therapy for treating malignancies
WO2017087885A1 (en) 2015-11-19 2017-05-26 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
AU2017205101B2 (en) 2016-01-08 2023-05-04 Breast Cancer Now Inhibitors of ataxia-telangiectasia mutated and Rad3-related protein kinase (ATR) for use in methods of treating cancer
ES2912909T3 (es) 2016-02-26 2022-05-30 Celgene Corp Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2018064589A1 (en) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
US10207998B2 (en) 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
AU2018219292B2 (en) 2017-02-08 2024-09-26 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation with heterobifunctional compounds
KR20190140438A (ko) 2017-02-28 2019-12-19 에피자임, 인코포레이티드 암 치료를 위한 smarca2의 저해
US11555031B2 (en) 2017-03-20 2023-01-17 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
US20200206344A1 (en) 2017-08-21 2020-07-02 Dana-Farber Cancer Institute, Inc. Methods for modulating the interaction between ews-fli1 and baf complexes
AU2018320673B2 (en) 2017-08-21 2023-03-30 Merck Patent Gmbh Benzimidazole derivatives as adenosine receptor antagonists
WO2019138017A1 (en) 2018-01-15 2019-07-18 Ucb Biopharma Sprl Fused imidazole derivatives as il-17 modulators
WO2019142192A1 (en) 2018-01-17 2019-07-25 Gavish-Galilee Bio Applications Ltd. New methionine metabolic pathway inhibitors
WO2019152437A1 (en) 2018-01-30 2019-08-08 Foghorn Therapeutics Inc. Compounds and uses thereof
JP2021512167A (ja) 2018-01-30 2021-05-13 フォグホーン セラピューティクス インコーポレイテッドＦｏｇｈｏｒｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 障害を治療するための方法及び化合物
US11447502B2 (en) * 2018-05-25 2022-09-20 Rutgers, The State University Of New Jersey Antibacterial agents: dual-targeted RNA polymerase inhibitors
WO2019246430A1 (en) 2018-06-21 2019-12-26 Foghorn Therapeutics Inc. Methods of treating disorders
US20210260171A1 (en) 2018-06-21 2021-08-26 Foghorn Therapeutics Inc. Methods of treating disorders
CN118666832A (zh) 2018-08-17 2024-09-20 诺华股份有限公司 作为smarca2/brm atp酶抑制剂的脲化合物和组合物
WO2020041756A1 (en) 2018-08-23 2020-02-27 Foghorn Therapeutics Inc. Methods of treating cancer
WO2020081556A2 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Non-canonical swi/snf complex and uses thereof
WO2020081588A1 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
JP2022508155A (ja) 2018-11-21 2022-01-19 フォグホーン セラピューティクス インコーポレイテッド がんを治療する方法
BR112021010453A2 (pt) 2018-12-19 2021-08-24 Leo Pharma A/S Composto, e, composição farmacêutica
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
ES3032327T3 (en) 2019-01-29 2025-07-17 Foghorn Therapeutics Inc Compounds and uses thereof
WO2020160100A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
PH12022550578A1 (en) 2019-09-12 2024-02-19 Aurigene Discovery Tech Ltd Method for identifying responders to smarca2/4 degraders
US20220396604A1 (en) 2019-10-25 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions comprising modified smarcb1 and uses thereof
EA202192101A1 (ru) 2019-11-21 2021-12-09 Фогхорн Терапьютикс Инк. Соединения и их применение
EP4097096A4 (en) 2020-01-29 2024-02-28 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
CN115297861B (zh) 2020-01-29 2024-07-12 福宏治疗公司 化合物及其用途
US20230149414A1 (en) 2020-01-29 2023-05-18 Foghorn Therapeutics Inc. Compounds and uses thereof
CA3167275A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US20230121497A1 (en) 2020-01-29 2023-04-20 Foghorn Therapeutics Inc. Compounds and uses thereof
AU2021214767A1 (en) 2020-01-29 2022-07-28 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021183218A1 (en) 2020-03-13 2021-09-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating the interaction between ss18-ssx fusion oncoprotein and nucleosomes
CN115867314A (zh) 2020-05-20 2023-03-28 福宏治疗公司 治疗癌症的方法
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
JP2024509268A (ja) 2021-03-09 2024-02-29 フォグホーン セラピューティクス インコーポレイテッド 結晶形、それらを含有する組成物、及びそれらの使用方法
WO2022192621A1 (en) 2021-03-12 2022-09-15 Celgene Corporation Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles
WO2022198043A1 (en) 2021-03-19 2022-09-22 Foghorn Therapeutics Inc. Therapeutic regimens of an inhibitor of the enzymatic activity of brg1 and brm
WO2023009834A2 (en) 2021-07-29 2023-02-02 Foghorn Therapeutics Inc. Methods of treating cancer
EP4504210A4 (en) 2022-04-08 2026-04-01 Foghorn Therapeutics Inc METHODS OF TREATMENT OF A SUBJECT WITH CLINICALLY SIGNIFICANT SIGNS AND SYMPTOMS ASSOCIATED WITH BLOOD CELL DIFFERENTIATION
WO2023196560A1 (en) 2022-04-08 2023-10-12 Foghorn Therapeutics Inc. Methods of treating cancer
WO2023196565A1 (en) 2022-04-08 2023-10-12 Foghorn Therapeutics, Inc. Methods of treating cancer
CN119654785A (zh) 2022-07-29 2025-03-18 株式会社电装 电力转换装置
CN218451564U (zh) 2022-08-09 2023-02-07 宁波立奇电器有限公司 一种双锅双风道式空气炸锅
WO2024086577A1 (en) 2022-10-17 2024-04-25 Foghorn Therapeutics Inc. Methods of reducing or preventing metastases
WO2024216151A1 (en) 2023-04-13 2024-10-17 Foghorn Therapeutics Inc. Combination therapy for treating hematological cancers
WO2024216136A1 (en) 2023-04-13 2024-10-17 Foghorn Therapeutics Inc. Combination therapy for the treatment of hematological cancers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717642A (en) * 1969-07-22 1973-02-20 Warner Lambert Co N quinoline 5 aminooxazoles
CN103038231A (zh) * 2010-03-17 2013-04-10 台维克斯医疗公司 Hec1活性调节剂及其方法
CN105473141A (zh) * 2013-03-15 2016-04-06 实发生物医学公司 治疗和/或预防心血管疾病的抗pcsk9化合物和方法
WO2015120320A1 (en) * 2014-02-06 2015-08-13 Rutgers, The State University Of New Jersey Antibacterial agents: n(alpha)-aroyl-n-aryl-phenylalaninamides
CN107531668A (zh) * 2015-02-25 2018-01-02 基因泰克公司 治疗性哒嗪化合物及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEHMANN: "Reaction of Aminothiazoles with 5-Oxazolones", 《CHEMINFORM》 *

Also Published As

Publication number Publication date
JP2021512166A (ja) 2021-05-13
WO2019152437A1 (en) 2019-08-08
US20230138480A1 (en) 2023-05-04
EP3746124A1 (en) 2020-12-09
US11497752B2 (en) 2022-11-15
EP3746124A4 (en) 2021-10-27
US12383560B2 (en) 2025-08-12
US20210038611A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
CN112153984A (zh) 化合物及其用途
US12509453B2 (en) BRM/BRG1 inhibitors and uses thereof
JP7479486B2 (ja) 化合物およびその使用
CN116745288B (zh) 化合物及其用途
JP7600396B2 (ja) 化合物及びその使用
JP7531656B2 (ja) 化合物及びその使用
JP2023512038A (ja) 化合物及びその使用
KR20220133258A (ko) 화합물 및 이의 용도
CN115666575A (zh) 化合物及其用途
IL285177B1 (en) Compounds and their use
EA049084B1 (ru) Соединения и их применение
EA052989B1 (ru) Соединения и их применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination